This compound, known as Daclatasvir Intermediate 5, is a key synthetic intermediate in the production of Daclatasvir (BMS-790052). Daclatasvir is a direct-acting antiviral agent (DAA) and a first-in-class, highly potent NS5A replication complex inhibitor used for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. As a critical intermediate, its synthesis and purity are essential for the final manufacturing process of the active pharmaceutical ingredient (API). The compound's structure is integral to forming the core of the Daclatasvir molecule, which is designed to disrupt the function of the HCV NS5A protein, a vital component for viral replication and assembly. The development and use of this intermediate are closely tied to the pharmaceutical production of a major anti-HCV drug, highlighting its specific and high-value application within the pharmaceutical industry rather than as a general-purpose chemical building block.